Literature DB >> 27806847

False-positive results in diagnostic immunohistochemistry are related to horseradish peroxidase conjugates in commercially available assays.

Gerard Nuovo1.   

Abstract

False-positive results in diagnostic immunopathology can lead to unnecessary treatments. The purpose of this study was to do a side-by-side comparison of 10 different antibodies commonly used in the clinical laboratory altering only the horseradish peroxidase (HRP) conjugate. The automated Leica BOND-MAX platform was used to study serial sections from 203 tissues including controls compared in a blinded fashion using the HRP conjugates from Leica (Refine HRP), Ventana Medical Systems (Ultraview HRP), and Enzo Life Sciences (Polyview HRP). False-positive results, defined as signal from cases known to not contain the target, were noted in 23 (13%) of 171 cases with the Leica HRP, 62 (36%) of 171 cases with the Ventana HRP, and no cases with the Enzo HRP. Each data set was performed simultaneously allocating 1 tray for each of the 3 different HRP conjugates. HER2/neu analysis from triple-negative breast cancers were scored as positive by immunohistochemistry in 6 (24%) of 25 cases using either the Refine or Ultraview HRP and in 0 of 25 cases with the Enzo conjugate. It is concluded that false-positive results in a wide spectrum of diagnostic immunopathology tests can occur from 13% to 36% of cases with commonly used commercial assays based on the HRP conjugate.
Copyright © 2016 The Author. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  False negative; False positive; HER2/neu; Immunohistochemistry

Mesh:

Substances:

Year:  2016        PMID: 27806847     DOI: 10.1016/j.anndiagpath.2016.09.010

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

1.  Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma.

Authors:  Monika Szymonek; Artur Kowalik; Janusz Kopczyński; Danuta Gąsior-Perczak; Iwona Pałyga; Agnieszka Walczyk; Klaudia Gadawska-Juszczyk; Agnieszka Płusa; Ryszard Mężyk; Magdalena Chrapek; Stanisław Góźdź; Aldona Kowalska
Journal:  Oncotarget       Date:  2017-08-24

2.  miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.

Authors:  Young-Jun Jeon; Taewan Kim; Dongju Park; Gerard J Nuovo; Siyeon Rhee; Pooja Joshi; Bum-Kyu Lee; Johan Jeong; Sung-Suk Suh; Jeff E Grotzke; Sung-Hak Kim; Jieun Song; Hosung Sim; Yonghwan Kim; Yong Peng; Youngtae Jeong; Michela Garofalo; Nicola Zanesi; Jonghwan Kim; Guang Liang; Ichiro Nakano; Peter Cresswell; Patrick Nana-Sinkam; Ri Cui; Carlo M Croce
Journal:  Nat Commun       Date:  2018-11-30       Impact factor: 14.919

3.  Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.

Authors:  J Justin Mulvey; Cynthia M Magro; Lucy X Ma; Gerard J Nuovo; Rebecca N Baergen
Journal:  Ann Diagn Pathol       Date:  2020-04-25       Impact factor: 2.090

4.  A Standardization Protocol for the In Situ Detection of SARS-CoV2 RNA and Proteins.

Authors:  Gerard J Nuovo; David Suster; Esmerina Tili; Hamdy Awad; Cynthia Magro
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-02-01

5.  Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019.

Authors:  Cynthia M Magro; J Justin Mulvey; Jeffrey Laurence; Surya Seshan; A Neil Crowson; Andrew J Dannenberg; Steven Salvatore; Joanna Harp; Gerard J Nuovo
Journal:  Hum Pathol       Date:  2020-10-12       Impact factor: 3.466

6.  Patient-Specific Variables Determine the Extent of Cellular Senescence Biomarkers in Ovarian Tumors In Vivo.

Authors:  Paweł Uruski; Justyna Mikuła-Pietrasik; Eryk Naumowicz; Kamila Kaźmierczak; Andrey N Gaiday; Jan Królak; Błażej Nowakowski; Rafał Moszyński; Andrzej Tykarski; Krzysztof Książek
Journal:  Biomedicines       Date:  2021-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.